HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

In vivo effects of horse and rabbit antithymocyte globulin in patients with severe aplastic anemia.

Abstract
We recently reported that rabbit antithymocyte globulin was markedly inferior to horse antithymocyte globulin as a primary treatment for severe aplastic anemia. Here we expand on our findings in this unique cohort of patients. Rabbit antithymocyte globulin was detectable in plasma for longer periods than horse antithymocyte globulin; rabbit antithymocyte globulin in plasma retained functional capacity to bind to lymphocytes for up to 1 month, horse antithymocyte globulin for only about 2 weeks. In the first week after treatment there were much lower numbers of neutrophils in patients treated with rabbit antithymocyte globulin than in patients receiving horse antithymocyte globulin. Both antithymocyte globulins induced a "cytokine storm" in the first 2 days after administration. Compared with horse antithymocyte globulin, rabbit antithymocyte globulin was associated with higher levels of chemokine (C-C motif) ligand 4 during the first 3 weeks. Besides a much lower absolute number and a lower relative frequency of CD4(+) T cells, rabbit antithymocyte globulin induced higher frequencies of CD4(+)CD38(+), CD3(+)CD4(-)CD8(-) T cells, and B cells than did horse antithymocyte globulin. Serum sickness occurred around 2 weeks after infusion of both types of antithymocyte globulin. Human anti-antithymocyte globulin antibodies, especially of the IgM subtype, correlated with serum sickness, which appeared concurrently with clearance of antithymocyte globulin in blood and with the production of cytokines. In conclusion, rabbit and horse antithymocyte globulins have very different pharmacokinetics and effects on neutrophils, lymphocyte subsets, and cytokine release. These differences may be related to their efficacy in suppressing the immune system and restoring hematopoiesis in bone marrow failure. Clinicaltrials.gov identifier: NCT00260689.
AuthorsXingmin Feng, Phillip Scheinberg, Angelique Biancotto, Olga Rios, Sarah Donaldson, Colin Wu, Haiyun Zheng, Kazuya Sato, Danielle M Townsley, J Philip McCoy, Neal S Young
JournalHaematologica (Haematologica) Vol. 99 Issue 9 Pg. 1433-40 (Sep 2014) ISSN: 1592-8721 [Electronic] Italy
PMID24907357 (Publication Type: Clinical Trial, Journal Article, Research Support, N.I.H., Intramural)
CopyrightCopyright© Ferrata Storti Foundation.
Chemical References
  • Antilymphocyte Serum
  • Cytokines
  • Immunosuppressive Agents
Topics
  • Adolescent
  • Adult
  • Aged
  • Anemia, Aplastic (drug therapy, immunology, pathology)
  • Animals
  • Antilymphocyte Serum (administration & dosage, pharmacology)
  • Child
  • Child, Preschool
  • Cytokines (biosynthesis, metabolism)
  • Female
  • Horses
  • Humans
  • Immunosuppressive Agents (administration & dosage, pharmacokinetics, pharmacology)
  • Lymphocyte Count
  • Male
  • Middle Aged
  • Neutrophils (drug effects, immunology, pathology)
  • Rabbits
  • Severity of Illness Index
  • Species Specificity
  • T-Lymphocyte Subsets (drug effects, immunology, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: